【摘要】 创伤性脑损伤(TBI)是全球范围内导致高死亡率与长期残疾的主要病因之一。TBI的特点是因外部机械冲击导致的脑组织损伤，可能对功能性神经元造成不可逆损伤。继发性损伤所引起的级联反应是导致神经功能损伤、组织氧化应激和炎症水平升高的主要因素之一。促红细胞生成素(EPO)作为Ⅰ型细胞因子，通过多靶点神经保护机制减轻继发性神经损伤，是TBI极富潜力的治疗策略，其临床转化仍需克服造血副作用及递送效率瓶颈。本文综述了外源性给予EPO在TBI治疗中的研究进展。更多还原

【Abstract】 Traumatic brain injury(TBI) is one of the significant causes of mortality and disability worldwide. It is characterized by mechanical damage to the brain caused by external impact, which may result in irreversible harm to functional neurons. The cascade of reactions initiated by secondary injury is one of the primary factors leading to neural functional impairment and the elevation of oxidative stress and inflammatory levels. Erythropoietin(EPO), as a type I cytokine, mitigates secondary neuronal injury through multi-target neuroprotective mechanisms, representing a highly promising therapeutic strategy for TBI. However, its clinical translation still needs to address hematopoietic side effects and delivery efficiency bottlenecks. This review summarizes the research progress on exogenous EPO administration in TBI treatment.更多还原